预约演示

更新于：2025-05-07

Hemorrhagic Septicemia

出血性败血症

更新于：2025-05-07

基本信息

别名

Bacteremia, Hemorrhagic、Haemorrhagic Bacteremia、Haemorrhagic Septicaemia

+ [12]

简介

Any of several bacterial diseases, usually caused by PASTEURELLA MULTOCIDA, marked by the presence of hemorrhagic areas in the subcutaneous tissues, serous membranes, muscles, lymph glands, and throughout the internal organs. The diseases primarily affect animals and rarely humans.

关联

项与出血性败血症相关的药物

Avibactam Sodium/Ceftazidime

头孢他啶阿维巴坦钠

靶点

β-lactamase

作用机制

β-lactamase抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2015-02-25

Biapenem

比阿培南

靶点

PBPs

作用机制

PBPs抑制剂

在研机构

Meiji Seika Pharma Co., Ltd. [+1]

原研机构-

在研适应症

细菌感染 [+7]

非在研适应症

复杂的尿路感染

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期2001-10-02

Teicoplanin

替考拉宁

靶点-

作用机制

细胞壁抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期1998-04-10

100 项与出血性败血症相关的临床结果

登录后查看更多信息

100 项与出血性败血症相关的转化医学

登录后查看更多信息

0 项与出血性败血症相关的专利（医药）

登录后查看更多信息

1,186

项与出血性败血症相关的文献（医药）

2025-07-01·Fish & Shellfish Immunology

Characterization, microRNA profiling, and immunomodulatory role of plasma-derived exosomes from olive flounder (Paralichthys olivaceus) in response to viral hemorrhagic septicemia virus

Article

作者: De Zoysa, Mahanama ; Nikapitiya, Chamilani ; Jayathilaka, E H T Thulshan ; Edirisinghe, Shan Lakmal ; Oh, Chulhong

Viral hemorrhagic septicemia virus (VHSV) is a highly pathogenic virus that frequently infects olive flounder (Paralichthys olivaceus), causing viral hemorrhagic septicemia (VHS), and posing a significant threat to global aquaculture. This study characterizes plasma-derived exosomes from olive flounder following VHSV challenge (VHSV-Exo) or phosphate buffered saline (PBS) injection (PBS-Exo), comparing their morphology, physicochemical properties, molecular profiles, and immunomodulatory functions. Both PBS-Exo (118.3 ± 8.6 nm) and VHSV-Exo (82.6 ± 5.9 nm) exhibited the typical cup-shaped morphology of exosomes. The successful isolation and purity of exosomes were confirmed by the presence of exosome markers (CD81, CD9, and CD63) and the absence of albumin. High-throughput sequencing identified 13 differentially expressed (DE) microRNAs (miRNAs) between PBS-Exo and VHSV-Exo, including six upregulated and seven downregulated miRNAs (log₂ fold change ≥1 or ≤ -1). Toxicity assessments revealed that neither PBS-Exo nor VHSV-Exo were toxic to murine macrophage Raw 264.7 cells or zebrafish larvae at tested doses (up to 100 and 400 μg/mL, respectively). The absence of green fluorescence at 96 h post-treatment of VHSV-Exo indicated minimal reactive oxygen species generation, further supporting exosome safety. Functional studies demonstrated that both in vitro (Raw 264.7 cells) and in vivo (adult zebrafish) treatments with exosomes regulated immune-related genes and proteins expression. Notabaly, VHSV-Exo exhibited superior immunomodulatory effects, as evidenced by enhanced immune gene and protein expression. To our knowledge, this is the first study demonstrating the immunomodulatory potential of VHSV-Exo. These findings highlight VHSV-Exo as a promising immunomodulatory agent, with potential applications as a prophylactic vaccine candidate against VHSV infection in aquaculture.

2025-07-01·Fish & Shellfish Immunology

Bacillus subtilis supplemented feeding as a method to increase IgM titers and affinity in response to fish vaccination

Article

作者: Abós, Beatriz ; Serra, Claudia ; Morel, E ; Fouz, Belén ; Herranz-Jusdado, J Germán ; Nogales-Mérida, Silvia ; Ordás, M Camino ; Vicente-Gil, Samuel ; Nuñez-Ortiz, Noelia ; Díaz-Rosales, Patricia ; Tafalla, Carolina ; Simón, Rocío

In aquaculture, the use of probiotics in supplemented diets has been shown to be a suitable strategy to increase the immune status of fish and thereby reduce the impact of pathogens. Specifically, the immunostimulatory effects of the probiotic microorganism Bacillus subtilis have been widely confirmed both in vitro and in vivo in many aquacultured species. However, whether feeding fish with probiotic-enriched diets affects the adaptive immune response mounted to a vaccine has been scarcely addressed in fish. Therefore, in this study, we addressed this using rainbow trout (Oncorhynchus mykiss) as a model. To this aim, fish were fed a probiotic-supplemented diet or a control diet for 30 days and thereafter immunized through different administration routes with different antigenic models, including 2,4,6-trinitrophenyl lipopolysaccharide (TNP-LPS), a Yersinia ruckeri bacterin or a DNA vaccine against viral haemorrhagic septicaemia virus (VHSV). The effects of the B. subtilis-supplemented diet on the systemic specific IgM responses mounted were then established. For TNP-LPS, we also determined the effects of the diet on antibody affinity using a BIAcore instrument, which allows direct detection of antibody-antigen interactions by surface plasmon resonance (SPR) changes. The results presented reveal beneficial effects of feeding this probiotic on the vaccine-induced antibody response and point to the usefulness of designing holistic vaccination protocols that not only focus on antigen optimization or administration regimes, but also include diet composition as an important factor to influence the outcome of the immunization strategy.

2025-06-01·Fish & Shellfish Immunology

Establishment and identification of spleen cell line from tiger puffer fish (Takifugu rubripes) and immune transcriptome response to IHNV

Article

作者: Liu, Kaiqiang ; Zhang, Jingjing ; Wang, Qian ; Dong, Caichao ; He, Yangbin ; Shao, Changwei ; Meng, Bo ; Yang, Yu ; Liu, Yuyan ; Ji, Honglong ; Lin, Lei

The tiger puffer fish (Takifugu rubripes) is highly valued both economically and for its culinary appeal. However, it currently faces a significant risk of disease. This study aimed to establish a spleen cell line to aid in disease prevention and control for this species. We established a new stable cell line (TRSC) from the spleen tissue of the tiger puffer fish. The TRSC cells exhibited stable growth over more than 90 generations in L-15 medium supplemented with 4 ng/mL recombinant human basic fibroblast growth factor (bFGF) and 2 ng/mL recombinant human leukemia inhibitory factor (LIF) at 24 °C. Chromosomal analysis revealed a diploid number of 2n = 44. The TRSC cells were susceptibly infected by both viral hemorrhagic septicemia virus (VHSV) and infectious hematopoietic necrosis virus (IHNV), exhibiting a clear cytopathic effect (CPE). After 48 h of infection, alterations in cell morphology and disintegration were observed. Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis revealed differential replication of the two viruses in TRSC cells. Transcriptome sequencing identified 1308 differentially expressed genes (DEGs) following IHNV infection, with 668 genes upregulated and 640 downregulated. These DEGs were significantly enriched in MAPK signaling pathway, p53 signaling pathway, and DNA replication and so on. The establishment of the TRSC cell line provides valuable insights into viral infection mechanisms, aids in the identification of key immune genes, and offers a more effective approach to disease control in aquaculture, supporting the sustainable development of the industry.

项与出血性败血症相关的新闻（医药）

2022-04-08

·医药观澜

盐野义新型抗生素在中国获批临床

中国国家药监局药品审评中心（CDE）官网公示，盐野义公司（Shionogi）5.1类新药注射用cefiderocol已获得临床试验默示许可，适用于在治疗选择有限的成人患者中由需氧革兰氏阴性病原体引起的感染。公开资料显示，这是一款新型铁载体头孢菌素类抗生素药物，已在海外获批多个适应症，包括用于治疗由革兰氏阴性菌造成的多种感染。抗生素耐药性（AMR）是一个急需解决的健康负担，它的发生与细菌产生超广谱β-内酰胺酶和碳青霉烯酶的耐药机制有关。由革兰氏阴性菌引发的感染对药物的耐药性正在逐步增强，如今更多革兰氏阴性病原体能够对多种抗生素产生耐药性，导致患者发病和死亡率的增加。因此，患者急需可以有效治疗耐药性细菌感染的新疗法。盐野义公司的cefiderocol（S-649266）是一款在研新型抗生素药物。根据该公司官网，该产品已在美国获批用于复杂尿路感染，包括肾盂肾炎和医院感染，以及没有或有限治疗选择的肺炎；在欧洲获批用于治疗选择有限的成年患者中由需氧革兰氏阴性菌引起的感染。公开资料显示，cefiderocol具有一种独特的机制，可以使药物穿过包括多种耐药性（MDR）菌株在内的革兰氏阴性菌病原体的细胞膜。这种独特机制的启发来自著名的“特洛伊木马”的故事。研究人员发现，当我们的身体受到急性感染时，免疫系统会在体内制造一个缺铁的环境，这就使得细菌不得不提高铁摄入量。这时，与铁元素结合的新型抗生素则乘虚而入，顺利通过细菌的层层防守，从内部将细菌杀死。这种机制可以使cefiderocol在细胞周质内达到一个较高的浓度，与受体顺利结合，并抑制细胞壁合成，还可以对抗包括金属β-及丝氨酸β-在内的β-内酰胺酶类。除此之外，该产品还显示出在体外针对包括抗碳青霉烯的不动杆菌在内的多种革兰氏阴性菌的良好效果。来自APEKS-cUTI和APEKS-NP和CRREDIBLE-CR这三项临床研究的数据表明，cefiderocol对以下类型由需氧革兰氏阴性菌引起的感染患者有效：复杂性尿路感染（cUTI）、医院获得性肺炎（HAP）、呼吸机相关性肺炎（VAP），以及由复杂腹腔内感染（cIAI）和皮肤及皮肤结构感染（SSSI）引起的败血症、菌血症等。其中一项研究纳入了由多重耐药病原体引起的革兰氏阴性感染患者。本次cefiderocol在中国获批开展临床试验，意味着该产品也即将在中国进入临床开发。公开资料显示，目前cefiderocol还在美国和欧洲开展3期临床试验，针对儿童患者因多重耐药革兰氏阴性菌引起的感染。希望cefiderocol在临床研究中进展顺利，早日为更多耐药性感染患者带来新的治疗选择。参考资料： [1] 中国国家药监局药品审评中心（CDE）官网.Retrieved Apr 7，2022, from https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d [2] 盐野义公司官网. from https://www.shionogi.com/global/en/innovation/pipeline.html[3]Shionogi Receives European Commission Marketing Authorisation for FETCROJA® (cefiderocol) for the Treatment of Infections Due to Aerobic Gram-negative Bacteria in Adults With Limited Treatment Options. Retrieved April 27, 2020 from https://www.businesswire.com/news/home/20200427005719/en/Shionogi-Receives-European-Commission-Marketing-Authorisation-FETCROJA%C2%AE 内容来源于网络，如有侵权，请联系删除，谢谢

创新药抗体